Clinical characteristics of 16 lupus nephritis (LN) patients who had received prednisolone and sirolimus treatment.
| Age, yrs | 49.0 ± 7.8 |
|---|---|
| Sex, F/M | 15:1 |
| Duration of SLE before sirolimus treatment, mos | 204.6 ± 113.7 |
| Class of LN | |
| Class III ± V or Class IV ± V | 14 |
| Class V | 2 |
| Immunosuppressive regimen prior to sirolimus treatment | |
| PSL + MMF | 4 |
| PSL + AZA | 4 |
| PSL + CNI | 3 |
| PSL alone | 4 |
| None | 1 |
| Indications for sirolimus treatment | |
| Malignancy | 7 |
| Intolerance to MMF | 6 |
| Intolerance to CNI | 3 |
| Clinical variables before initiation of sirolimus treatment | |
| Systolic blood pressure, mmHg | 114.2 ± 15.1 |
| Diastolic blood pressure, mmHg | 70.8 ± 10.6 |
| eGFR, ml/min/1.73 m2 | 58.6 ± 25.8 |
| Urine protein excretion, g/day | 1.8 ± 1.7 |
| Anti-dsDNA, IU/ml | 65.6 ± 72.8 |
| Serum C3, mg/dl | 77.1 ± 27.2 |
| Fasting glucose, mmol/l | 4.5 ± 0.4 |
| Total cholesterol, mmol/l | 5.1 ± 0.8 |
| LDL cholesterol, mmol/l | 2.8 ± 0.8 |
| Triglyceride, mmol/l | 1.4 ± 0.9 |
SLE: systemic lupus erythematosus; AZA: azathioprine; CNI: calcineurin inhibitors; MMF: mycophenolate mofetil; PSL: prednisolone; eGFR: estimated glomerular filtration rate; LDL: low-density lipoprotein.